COMMUNIQUÉS West-GlobeNewswire

Zelluna ASA: Cancellation of subsequent repair offering
09/12/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836
09/12/2025
Target enrollment of 2,850 healthy volunteers completed across multiple European countries Topline data read-out expected by mid-2026, subject to influenza circulation during the winter season Lyon, France and Liège, [...]
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
09/12/2025
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a benefit in a [...]
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
09/12/2025
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test will help improve [...]
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
09/12/2025
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur Finalisation de la phase 3 de Tedopi® dans le cancer du poumon non à petites cellules Une ou deux nouvelles [...]
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
09/12/2025
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty indications for Lusvertikimab [...]
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
09/12/2025
Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population [...]
Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH
09/12/2025
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) Of the 6 patients, 5 had a [...]
Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders
09/12/2025
London, UK – 9 th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle [...]
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
09/12/2025
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, [...]
Relation announces further $26 million investment
09/12/2025
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC and Magnetic [...]
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
09/12/2025
BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies [...]
Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting
09/12/2025
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias Findings underscore potential to address unmet needs in multiple hematological malignancies, [...]
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
09/12/2025
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO
09/12/2025
Zwerling expected to guide the Company to its commercial launch APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing [...]
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
09/12/2025
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in [...]
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
09/12/2025
By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectively High-risk IKZF1 plus patients showed 90% [...]
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
09/12/2025
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular [...]
A-Team Home Care Turns Nine and Shines—Earning Philadelphia100 Top-20, Philadelphia Inquirer's Best in Philly Home Care, and 2025 Best Employer & Senior Care Titles in Bucks Happenings
08/12/2025
Marking nearly a decade of service, A-Team Home Care celebrates sweeping regional awards that underscore its impact on clients, caregivers, and the Philadelphia community. Philadelphia, PA , Dec. 08, 2025 (GLOBE [...]

Pages